Xtant Medical Holdings, Inc.: Form 10-K/A for the period ended Dec 31, 2017
Filed with the SEC on Apr 5, 2018 and accepted by EDGAR at Apr 5, 2018, 15:06 ET.
Sections
No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 12 months2017-01-01 to 2017-12-31 | $32.5m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2017-01-01 to 2017-12-31 | $50.1m | us-gaap:GrossProfit |
| Research and development | 12 months2017-01-01 to 2017-12-31 | $2.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2017-01-01 to 2017-12-31 | −$37.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2017-01-01 to 2017-12-31 | $14.7m | us-gaap:InterestExpense |
| Income tax | 12 months2017-01-01 to 2017-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2017-01-01 to 2017-12-31 | −$52.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2017-01-01 to 2017-12-31 | −$34.76 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2017-01-01 to 2017-12-31 | −$34.76 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2017-01-01 to 2017-12-31 | 1,507,769 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2017-01-01 to 2017-12-31 | −$543.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2017-01-01 to 2017-12-31 | $1.6m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2017-12-31 | $2.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-12-31 | $39.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-12-31 | $105.7m | us-gaap:Assets |
| Current liabilities | At period end2017-12-31 | $25.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-12-31 | $164.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-12-31 | −$58.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001144204-18-019363. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.